Cardiorenal syndrome type 3: pathophysiologic and epidemiologic considerations

Area of Science:

• Cardiology
• Nephrology
• Pathophysiology

Background:

• Cardiorenal syndrome (CRS) type 3 involves acute kidney injury (AKI) precipitating acute cardiac injury.
• The precise pathophysiologic mechanisms linking AKI to cardiac dysfunction remain incompletely understood.
• Baseline patient susceptibility significantly influences the risk of cardiac events following AKI.

Framework:

• Experimental data suggest AKI directly induces cardiac injury via inflammatory mediators, oxidative stress, apoptosis, and neuroendocrine activation.
• AKI-associated physiological derangements, including volume overload, metabolic acidosis, uremic toxin retention, hyperkalemia, and hypocalcemia, indirectly impair cardiac function.
• Alterations in coronary vasoreactivity, ventricular remodeling, and fibrosis are also implicated in AKI's negative cardiac effects.

Implementation:

• AKI can impact cardiac function by altering drug pharmacokinetics and pharmacodynamics.
• Understanding these complex interactions is crucial for managing patients with cardiorenal conditions.

Implications:

• Further experimental, translational, and epidemiological studies are essential to elucidate the mechanisms of AKI-induced cardiac events.
• Improved understanding will guide the development of targeted therapies and enhance outcomes for patients experiencing cardiorenal syndrome type 3.